10x Genomics, Inc. (TXG) Stock
TXG Key Statistics
About 10x Genomics, Inc.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
CEO: Serge Saxonov. Company website
TXG — Frequently Asked Questions
What is the TXG stock price today?
10x Genomics, Inc. (TXG) trades at $76.60, down 0.48% on the day, as of Sep 20, 2026 15:01 UTC.
What is 10x Genomics, Inc.'s market cap?
10x Genomics, Inc. has a market capitalisation of $9.72B, calculated from the live TXG share price and shares outstanding.
What is the P/E ratio of TXG?
TXG has no meaningful price-to-earnings ratio: 10x Genomics, Inc. lost $0.59 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does 10x Genomics, Inc. make?
10x Genomics, Inc. generated revenue of $616.91M over the trailing twelve months, which puts the stock at 15.76 times sales.
What is the 52-week range for TXG?
TXG has traded between $11.16 and $79.94 over the past 52 weeks, and the last price is 4.2% below that high.
Is 10x Genomics, Inc. profitable?
No. 10x Genomics, Inc. is loss-making, with a net margin of -12.18% over the trailing twelve months.
What is the analyst price target for TXG?
Wall Street analysts rate TXG Hold, with an average price target of $53.33, 30.4% below the current price.
What sector is 10x Genomics, Inc. in?
10x Genomics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of 10x Genomics, Inc.?
Serge Saxonov is the chief executive of 10x Genomics, Inc., which employs 1,178 people.
Where can I track TXG in real time?
QFI Terminal shows TXG with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TXG live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TXG in Terminal See plans